Your session is about to expire
← Back to Search
Other
Tilpisertib for Ulcerative Colitis (PALEKONA Trial)
Phase 2
Recruiting
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Individuals assigned male at birth, or nonpregnant, nonlactating individuals assigned female at birth, 18 to 75 years of age based on the date of the screening visit.
Moderately to severely active UC as determined during screening with a modified Mayo Clinic Score based on the sum of Stool Frequency, Rectal Bleeding, and Endoscopic Finding of 5 to 9 points and an endoscopic subscore of 2 to 3 (determined by central reader).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Summary
This trial will study the effectiveness and safety of a potential medication for ulcerative colitis. Participants will be randomly given the drug or a placebo.
Who is the study for?
This trial is for adults aged 18-75 with moderate to severe ulcerative colitis confirmed by endoscopy. Participants must have tried at least one advanced UC therapy without success, but not more than three. They should have had a colonoscopy in the last two years if they've had UC for over eight years.
What is being tested?
The study tests Tilpisertib Fosmecarbil's effectiveness and safety against a placebo in treating ulcerative colitis. The main goal is to see if patients show clinical improvement after 12 weeks of treatment compared to those taking the placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a man, or a woman not pregnant or breastfeeding, aged 18-75.
Select...
My ulcerative colitis is moderate to severe, based on a specific scoring system.
Select...
I have had ulcerative colitis for at least 3 months, confirmed by tests, affecting at least 15 cm from the anal verge.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12
Secondary study objectives
Proportion of Participants Achieving Clinical Remission Per Modified Mayo Clinic Score at Week 12
Proportion of Participants Achieving Endoscopic Response at Week 12
Proportion of Participants Achieving Histologic Endoscopic Mucosal Improvement at Week 12
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Tilpisertib Fosmecarbil Dose CExperimental Treatment1 Intervention
Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose C for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Group II: Tilpisertib Fosmecarbil Dose BExperimental Treatment1 Intervention
Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose B for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Group III: Tilpisertib Fosmecarbil Dose AExperimental Treatment1 Intervention
Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose A for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Group IV: Tilpisertib Fosmecarbil PlaceboPlacebo Group2 Interventions
Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil placebo for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved Clinical Response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve Clinical Response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Find a Location
Who is running the clinical trial?
Gilead SciencesLead Sponsor
1,134 Previous Clinical Trials
867,783 Total Patients Enrolled
7 Trials studying Colitis
3,233 Patients Enrolled for Colitis
Gilead Study DirectorStudy DirectorGilead Sciences
360 Previous Clinical Trials
192,213 Total Patients Enrolled
6 Trials studying Colitis
3,205 Patients Enrolled for Colitis
Share this study with friends
Copy Link
Messenger